gatifloxacin has been researched along with Koch's Disease in 25 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medline, PubMed, Embase, and Cochrane Library were searched with the keyword such as "Levofloxacin," "Moxifloxacin," "Gatifloxacin," and "tuberculosis", through June 1992 to 2017." | 9.22 | The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis. ( He, Y; Li, X, 2022) |
| "Gatifloxacin previously demonstrated good in vitro and in vivo activities against Mycobacterium tuberculosis." | 7.74 | Gatifloxacin in combination with rifampicin in a murine tuberculosis model. ( Cynamon, M; Shoen, C; Sklaney, MR, 2007) |
| "The use of gatifloxacin (GAT) in combination with ethionamide (ETA) with or without pyrazinamide (PZA) for a 12-week treatment period followed by an 8-week observation period was evaluated in a model of tuberculosis in mice." | 7.72 | Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. ( Cynamon, MH; Sklaney, M, 2003) |
| "The in vitro activity of moxifloxacin, gatifloxacin, levofloxacin and linezolid was evaluated against 234 strains of Mycobacterium tuberculosis isolated in the Southeast of Spain." | 7.71 | In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. ( López, M; Rodríguez, JC; Royo, G; Ruiz, M, 2002) |
| "Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against Mycobacterium tuberculosis." | 7.71 | In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. ( Alvirez-Freites, EJ; Carter, JL; Cynamon, MH, 2002) |
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 5.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| "Medline, PubMed, Embase, and Cochrane Library were searched with the keyword such as "Levofloxacin," "Moxifloxacin," "Gatifloxacin," and "tuberculosis", through June 1992 to 2017." | 5.22 | The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis. ( He, Y; Li, X, 2022) |
" In this study, ACH-702 was found to have promising in vitro antibacterial activity against Mycobacterium tuberculosis, with MICs of | 3.76 | In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. ( Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA, 2010) | |
| "Gatifloxacin previously demonstrated good in vitro and in vivo activities against Mycobacterium tuberculosis." | 3.74 | Gatifloxacin in combination with rifampicin in a murine tuberculosis model. ( Cynamon, M; Shoen, C; Sklaney, MR, 2007) |
| "The use of gatifloxacin (GAT) in combination with ethionamide (ETA) with or without pyrazinamide (PZA) for a 12-week treatment period followed by an 8-week observation period was evaluated in a model of tuberculosis in mice." | 3.72 | Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. ( Cynamon, MH; Sklaney, M, 2003) |
| "The in vitro activity of moxifloxacin, gatifloxacin, levofloxacin and linezolid was evaluated against 234 strains of Mycobacterium tuberculosis isolated in the Southeast of Spain." | 3.71 | In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. ( López, M; Rodríguez, JC; Royo, G; Ruiz, M, 2002) |
| "Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against Mycobacterium tuberculosis." | 3.71 | In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. ( Alvirez-Freites, EJ; Carter, JL; Cynamon, MH, 2002) |
| "Ineffectively treated tuberculosis (TB) is associated with substantial morbidity and mortality." | 2.53 | Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy. ( Corelli, F; Frosini, M; Saponara, S; Sgaragli, G, 2016) |
| "Tuberculosis is a major disease causing every year 1." | 2.48 | Tuberculosis: the drug development pipeline at a glance. ( Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N, 2012) |
| "Ciprofloxacin and ofloxacin were classified as older-generation fluoroquinolones; levofloxacin, moxifloxacin and gatifloxacin were considered newer agents." | 1.39 | Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. ( Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV, 2013) |
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 1.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pichota, A | 1 |
| Duraiswamy, J | 1 |
| Yin, Z | 1 |
| Keller, TH | 1 |
| Alam, J | 1 |
| Liung, S | 1 |
| Lee, G | 1 |
| Ding, M | 1 |
| Wang, G | 1 |
| Chan, WL | 1 |
| Schreiber, M | 1 |
| Ma, I | 1 |
| Beer, D | 1 |
| Ngew, X | 1 |
| Mukherjee, K | 1 |
| Nanjundappa, M | 1 |
| Teo, JW | 1 |
| Thayalan, P | 1 |
| Yap, A | 1 |
| Dick, T | 1 |
| Meng, W | 1 |
| Xu, M | 1 |
| Koehn, J | 1 |
| Pan, SH | 1 |
| Clark, K | 1 |
| Xie, X | 1 |
| Shoen, C | 2 |
| Cynamon, M | 2 |
| van den Boogaard, J | 1 |
| Kibiki, GS | 1 |
| Kisanga, ER | 1 |
| Boeree, MJ | 1 |
| Aarnoutse, RE | 1 |
| Pucci, MJ | 1 |
| Ackerman, M | 1 |
| Thanassi, JA | 1 |
| Shoen, CM | 2 |
| Cynamon, MH | 4 |
| Villemagne, B | 1 |
| Crauste, C | 1 |
| Flipo, M | 1 |
| Baulard, AR | 1 |
| Déprez, B | 1 |
| Willand, N | 1 |
| Hu, YQ | 1 |
| Zhang, S | 1 |
| Zhao, F | 1 |
| Gao, C | 1 |
| Feng, LS | 2 |
| Lv, ZS | 1 |
| Xu, Z | 1 |
| Wu, X | 1 |
| Fan, YL | 1 |
| Wu, JB | 1 |
| Cheng, XW | 1 |
| Zhang, FZ | 1 |
| Girase, PS | 1 |
| Dhawan, S | 1 |
| Kumar, V | 1 |
| Shinde, SR | 1 |
| Palkar, MB | 1 |
| Karpoormath, R | 1 |
| He, Y | 1 |
| Li, X | 1 |
| Marcianes, P | 1 |
| Negro, S | 1 |
| Barcia, E | 1 |
| Montejo, C | 1 |
| Fernández-Carballido, A | 1 |
| Alvarez-Uria, G | 1 |
| Midde, M | 1 |
| van der Heijden, YF | 1 |
| Maruri, F | 1 |
| Blackman, A | 1 |
| Mitchel, E | 1 |
| Bian, A | 1 |
| Shintani, AK | 1 |
| Eden, S | 1 |
| Warkentin, JV | 1 |
| Sterling, TR | 1 |
| Ruan, Q | 1 |
| Liu, Q | 1 |
| Sun, F | 1 |
| Shao, L | 1 |
| Jin, J | 1 |
| Yu, S | 1 |
| Ai, J | 1 |
| Zhang, B | 1 |
| Zhang, W | 1 |
| Sgaragli, G | 1 |
| Frosini, M | 1 |
| Saponara, S | 1 |
| Corelli, F | 1 |
| Poissy, J | 1 |
| Aubry, A | 1 |
| Fernandez, C | 1 |
| Lott, MC | 1 |
| Chauffour, A | 1 |
| Jarlier, V | 1 |
| Farinotti, R | 1 |
| Veziris, N | 1 |
| Sokolova, GB | 1 |
| Maliev, BM | 1 |
| Mozhokina, GN | 1 |
| Elistratova, NA | 1 |
| Solov'eva, IP | 1 |
| Bugaenko, SE | 1 |
| Merle, CS | 1 |
| Sismanidis, C | 1 |
| Sow, OB | 1 |
| Gninafon, M | 1 |
| Horton, J | 1 |
| Lapujade, O | 1 |
| Lo, MB | 1 |
| Mitchinson, DA | 1 |
| Perronne, C | 1 |
| Portaels, F | 1 |
| Odhiambo, J | 1 |
| Olliaro, P | 1 |
| Rustomjee, R | 1 |
| Lienhardt, C | 1 |
| Fielding, K | 1 |
| Rodríguez, JC | 1 |
| Ruiz, M | 1 |
| López, M | 1 |
| Royo, G | 1 |
| Sklaney, M | 1 |
| DeStefano, MS | 1 |
| Sklaney, MR | 2 |
| Monica, BJ | 1 |
| Slee, AM | 1 |
| Lourenço, MC | 1 |
| Junior, IN | 1 |
| De Souza, MV | 1 |
| Alvirez-Freites, EJ | 1 |
| Carter, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| One-month Latent Tuberculosis Treatment for Renal Transplant Candidates[NCT05411744] | Phase 4 | 25 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis[NCT00216385] | Phase 3 | 2,070 participants | Interventional | 2005-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for gatifloxacin and Koch's Disease
| Article | Year |
|---|---|
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Des | 2009 |
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
Isoniazid derivatives and their anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Isoniazid; Mycobacterium tuberculosis; Tuber | 2017 |
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecula | 2018 |
An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.
Topics: Animals; Antitubercular Agents; Drug Design; Drug Discovery; Humans; Mycobacterium tuberculosis; Pip | 2021 |
The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Network M | 2022 |
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Hum | 2016 |
Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
Topics: Antitubercular Agents; Bacterial Proteins; Clinical Trials as Topic; Fluoroquinolones; Gatifloxacin; | 2016 |
Gatifloxacin.
Topics: Animals; Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Treatment Outcome; Tuberculo | 2008 |
2 trials available for gatifloxacin and Koch's Disease
| Article | Year |
|---|---|
A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project.
Topics: Africa; Antitubercular Agents; Directly Observed Therapy; Drug Therapy, Combination; Fluoroquinolone | 2012 |
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug | 2004 |
14 other studies available for gatifloxacin and Koch's Disease
| Article | Year |
|---|---|
Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results.
Topics: Amidohydrolases; Antitubercular Agents; Chemistry, Pharmaceutical; Crystallography, X-Ray; Drug Desi | 2008 |
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; | 2010 |
Potential Active Targeting of Gatifloxacin to Macrophages by Means of Surface-Modified PLGA Microparticles Destined to Treat Tuberculosis.
Topics: Animals; Drug Delivery Systems; Gatifloxacin; Macrophages; Male; Mice; Microscopy, Electron, Scannin | 2019 |
Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy.
Topics: Antitubercular Agents; Clinical Trials as Topic; Electrocardiography; Ethambutol; Female; Gatifloxac | 2018 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; | 2013 |
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; | 2010 |
[Efficacy and tolerance of rezonizate in complex with fluoroquinolones or mycobutin on a model of experimental murine tuberculosis].
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug Therapy, Combination; Drug Tolera | 2011 |
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistanc | 2002 |
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis.
Topics: Administration, Intranasal; Animals; Anti-Infective Agents; Antitubercular Agents; Colony-Forming Un | 2003 |
New tuberculosis therapy offers potential shorter treatment.
Topics: Antitubercular Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Fluoroquinolon | 2005 |
New tuberculosis therapy offers potential shorter treatment. Phase III trials planned in Africa.
Topics: Africa; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Fluoroquinolones; Gatiflo | 2006 |
In vitro activity of ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and gatifloxacin against multidrug-resistant Mycobacterium tuberculosis in Rio de Janeiro Brazil.
Topics: AIDS-Related Opportunistic Infections; Brazil; Drug Resistance, Microbial; Drug Resistance, Multiple | 2007 |
Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Mi | 2007 |
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug | 2002 |